Limits...
Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.

Ichikawa S, Fukuhara N, Katsushima H, Takahashi T, Yamamoto J, Yokoyama H, Sasaki O, Fukuhara O, Nomura J, Ishizawa K, Ichinohasama R, Muto A, Igarashi K, Harigae H - Cancer Sci. (2014)

Bottom Line: BACH2, a B cell-specific transcriptional repressor, plays a significant role in B cell maturation.There were no significant differences between the two groups with regard to clinical characteristics and outcomes.In cases with high BACH2 expression in GCB and non-GCB groups, the 3-year overall survival (OS) rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256).

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Show MeSH

Related in: MedlinePlus

Stratified analyses of the patients concering overall survival in association with BACH2 expression levels among germinal center B cell phenotype (GCB) and non-GCB groups. They are stratified by clinical stage (CS) (a), serum lactate dehydrogenase (LDH) (b), serum sIL-2R (c) and international prognostic index (IPI) score (d), respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317811&req=5

fig03: Stratified analyses of the patients concering overall survival in association with BACH2 expression levels among germinal center B cell phenotype (GCB) and non-GCB groups. They are stratified by clinical stage (CS) (a), serum lactate dehydrogenase (LDH) (b), serum sIL-2R (c) and international prognostic index (IPI) score (d), respectively.

Mentions: To elucidate the subgroups in which BACH2 can strongly predict the prognosis, we further analyzed the association between BACH2 expression levels and clinical outcome in various stratifications by log-rank analysis (Table 3 and Fig. 3). In any subgroups, a high level of BACH2 expression was associated with shorter survival time. In particular, a high level of BACH2 expression was a strong predictor of poor prognosis among the subgroups which had negative prognostic indicators such as higher serum LDH level, higher sIL-2R level and advanced clinical stage.


Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.

Ichikawa S, Fukuhara N, Katsushima H, Takahashi T, Yamamoto J, Yokoyama H, Sasaki O, Fukuhara O, Nomura J, Ishizawa K, Ichinohasama R, Muto A, Igarashi K, Harigae H - Cancer Sci. (2014)

Stratified analyses of the patients concering overall survival in association with BACH2 expression levels among germinal center B cell phenotype (GCB) and non-GCB groups. They are stratified by clinical stage (CS) (a), serum lactate dehydrogenase (LDH) (b), serum sIL-2R (c) and international prognostic index (IPI) score (d), respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317811&req=5

fig03: Stratified analyses of the patients concering overall survival in association with BACH2 expression levels among germinal center B cell phenotype (GCB) and non-GCB groups. They are stratified by clinical stage (CS) (a), serum lactate dehydrogenase (LDH) (b), serum sIL-2R (c) and international prognostic index (IPI) score (d), respectively.
Mentions: To elucidate the subgroups in which BACH2 can strongly predict the prognosis, we further analyzed the association between BACH2 expression levels and clinical outcome in various stratifications by log-rank analysis (Table 3 and Fig. 3). In any subgroups, a high level of BACH2 expression was associated with shorter survival time. In particular, a high level of BACH2 expression was a strong predictor of poor prognosis among the subgroups which had negative prognostic indicators such as higher serum LDH level, higher sIL-2R level and advanced clinical stage.

Bottom Line: BACH2, a B cell-specific transcriptional repressor, plays a significant role in B cell maturation.There were no significant differences between the two groups with regard to clinical characteristics and outcomes.In cases with high BACH2 expression in GCB and non-GCB groups, the 3-year overall survival (OS) rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256).

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Show MeSH
Related in: MedlinePlus